In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


bioMerieux's and Pierre Fabre's Surprise

Executive Summary

Alain Merieux and Pierre Fabre surprised the world by announcing the merger of the two companies they founded, bioMerieux, the world's eighth largest diagnostics company, and Pierre Fabre, the second largest pharmaceutical house in France. The stated purpose of the proposed merger is to allow both companies, which will have combined sales of $1.6 billion, to better compete in consolidating industries than either could on its own. They will focus on four therapeutic areas, with a goal of linking diagnostics to therapeutics. The companies are unlikely partners from a strategic point of view: bioMerieux makes in vitro diagnostics instruments and reagents, while Pierre Fabre is a mid-sized pharma company.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts